PMID- 33031500
OWN - NLM
STAT- MEDLINE
DCOM- 20211213
LR  - 20221207
IS  - 1537-6591 (Electronic)
IS  - 1058-4838 (Print)
IS  - 1058-4838 (Linking)
VI  - 73
IP  - 11
DP  - 2021 Dec 6
TI  - Compassionate Use of Remdesivir in Pregnant Women With Severe Coronavirus Disease 
      2019.
PG  - e3996-e4004
LID - 10.1093/cid/ciaa1466 [doi]
AB  - BACKGROUND: Remdesivir is efficacious for severe coronavirus disease 2019 
      (COVID-19) in adults, but data in pregnant women are limited. We describe 
      outcomes in the first 86 pregnant women with severe COVID-19 who were treated 
      with remdesivir. METHODS: The reported data span 21 March to 16 June 2020 for 
      hospitalized pregnant women with polymerase chain reaction-confirmed severe acute 
      respiratory syndrome coronavirus 2 infection and room air oxygen saturation </=94% 
      whose clinicians requested remdesivir through the compassionate use program. The 
      intended remdesivir treatment course was 10 days (200 mg on day 1, followed by 
      100 mg for days 2-10, given intravenously). RESULTS: Nineteen of 86 women 
      delivered before their first dose and were reclassified as immediate "postpartum" 
      (median postpartum day 1 [range, 0-3]). At baseline, 40% of pregnant women 
      (median gestational age, 28 weeks) required invasive ventilation, in contrast to 
      95% of postpartum women (median gestational age at delivery 30 weeks). By day 28 
      of follow-up, the level of oxygen requirement decreased in 96% and 89% of 
      pregnant and postpartum women, respectively. Among pregnant women, 93% of those 
      on mechanical ventilation were extubated, 93% recovered, and 90% were discharged. 
      Among postpartum women, 89% were extubated, 89% recovered, and 84% were 
      discharged. Remdesivir was well tolerated, with a low incidence of serious 
      adverse events (AEs) (16%). Most AEs were related to pregnancy and underlying 
      disease; most laboratory abnormalities were grade 1 or 2. There was 1 maternal 
      death attributed to underlying disease and no neonatal deaths. CONCLUSIONS: Among 
      86 pregnant and postpartum women with severe COVID-19 who received 
      compassionate-use remdesivir, recovery rates were high, with a low rate of 
      serious AEs.
CI  - (c) The Author(s) 2020. Published by Oxford University Press for the Infectious 
      Diseases Society of America.
FAU - Burwick, Richard M
AU  - Burwick RM
AD  - Cedars Sinai Medical Center, Obstetrics and Gynecology, Los Angeles, California, 
      USA.
FAU - Yawetz, Sigal
AU  - Yawetz S
AD  - Brigham and Women's Hospital, Department of Medicine, Boston, Massachusetts, USA.
AD  - Harvard Medical School, Boston, Massachusetts, USA.
FAU - Stephenson, Kathryn E
AU  - Stephenson KE
AD  - Harvard Medical School, Boston, Massachusetts, USA.
AD  - Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
FAU - Collier, Ai-Ris Y
AU  - Collier AY
AD  - Harvard Medical School, Boston, Massachusetts, USA.
AD  - Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
FAU - Sen, Pritha
AU  - Sen P
AD  - Harvard Medical School, Boston, Massachusetts, USA.
AD  - Massachusetts General Hospital, Boston, Massachusetts, USA.
FAU - Blackburn, Brian G
AU  - Blackburn BG
AD  - Stanford University, Stanford, California, USA.
FAU - Kojic, E Milunka
AU  - Kojic EM
AD  - Mount Sinai Morningside and Mount Sinai West, New York, New York, USA.
FAU - Hirshberg, Adi
AU  - Hirshberg A
AD  - Perelman School of Medicine, University of Pennsylvania, Philadelphia, 
      Pennsylvania, USA.
FAU - Suarez, Jose F
AU  - Suarez JF
AD  - Stanford University, Stanford, California, USA.
FAU - Sobieszczyk, Magdalena E
AU  - Sobieszczyk ME
AD  - Columbia University, New York, New York, USA.
FAU - Marks, Kristen M
AU  - Marks KM
AD  - Weill Cornell Medicine, New York, New York, USA.
FAU - Mazur, Shawn
AU  - Mazur S
AD  - NewYork Presbyterian/Weill Cornell Medical Center, New York, New York, USA.
FAU - Big, Cecilia
AU  - Big C
AD  - Beaumont Hospital, Dearborn, Michigan, USA.
FAU - Manuel, Oriol
AU  - Manuel O
AD  - Lausanne University Hospital, Lausanne, Switzerland.
FAU - Morlin, Gregory
AU  - Morlin G
AD  - Valley Medical Center, Renton, Washington, USA.
FAU - Rose, Suzanne J
AU  - Rose SJ
AD  - Stamford Health, Stamford, Connecticut, USA.
FAU - Naqvi, Mariam
AU  - Naqvi M
AD  - Cedars Sinai Medical Center, Obstetrics and Gynecology, Los Angeles, California, 
      USA.
FAU - Goldfarb, Ilona T
AU  - Goldfarb IT
AD  - Harvard Medical School, Boston, Massachusetts, USA.
AD  - Massachusetts General Hospital, Boston, Massachusetts, USA.
FAU - DeZure, Adam
AU  - DeZure A
AD  - Gilead Sciences Inc, Foster City, California, USA.
FAU - Telep, Laura
AU  - Telep L
AD  - Gilead Sciences Inc, Foster City, California, USA.
FAU - Tan, Susanna K
AU  - Tan SK
AD  - Gilead Sciences Inc, Foster City, California, USA.
FAU - Zhao, Yang
AU  - Zhao Y
AD  - Gilead Sciences Inc, Foster City, California, USA.
FAU - Hahambis, Tom
AU  - Hahambis T
AD  - Gilead Sciences Inc, Foster City, California, USA.
FAU - Hindman, Jason
AU  - Hindman J
AD  - Gilead Sciences Inc, Foster City, California, USA.
FAU - Chokkalingam, Anand P
AU  - Chokkalingam AP
AD  - Gilead Sciences Inc, Foster City, California, USA.
FAU - Carter, Christoph
AU  - Carter C
AD  - Gilead Sciences Inc, Foster City, California, USA.
FAU - Das, Moupali
AU  - Das M
AD  - Gilead Sciences Inc, Foster City, California, USA.
FAU - Osinusi, Anu O
AU  - Osinusi AO
AD  - Gilead Sciences Inc, Foster City, California, USA.
FAU - Brainard, Diana M
AU  - Brainard DM
AD  - Gilead Sciences Inc, Foster City, California, USA.
FAU - Varughese, Tilly A
AU  - Varughese TA
AD  - Rutgers New Jersey Medical School, Newark, New Jersey, USA.
FAU - Kovalenko, Olga
AU  - Kovalenko O
AD  - Rutgers New Jersey Medical School, Newark, New Jersey, USA.
FAU - Sims, Matthew D
AU  - Sims MD
AD  - Oakland University William Beaumont School of Medicine, Rochester, Michigan, USA.
FAU - Desai, Samit
AU  - Desai S
AD  - Hackensack Meridian, Hackensack University Medical Center, Hackensack, New 
      Jersey, USA.
FAU - Swamy, Geeta
AU  - Swamy G
AD  - Duke University School of Medicine, Durham, North Carolina, USA.
FAU - Sheffield, Jeanne S
AU  - Sheffield JS
AD  - Johns Hopkins Medicine, Baltimore, Maryland, USA.
FAU - Zash, Rebecca
AU  - Zash R
AD  - Harvard Medical School, Boston, Massachusetts, USA.
AD  - Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
FAU - Short, William R
AU  - Short WR
AD  - Perelman School of Medicine, University of Pennsylvania, Philadelphia, 
      Pennsylvania, USA.
LA  - eng
GR  - Gilead Sciences/
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Infect Dis
JT  - Clinical infectious diseases : an official publication of the Infectious Diseases 
      Society of America
JID - 9203213
RN  - 3QKI37EEHE (remdesivir)
RN  - 415SHH325A (Adenosine Monophosphate)
RN  - OF5P57N2ZX (Alanine)
SB  - IM
MH  - Adenosine Monophosphate/analogs & derivatives
MH  - Adult
MH  - Alanine/analogs & derivatives
MH  - Compassionate Use Trials
MH  - Female
MH  - Humans
MH  - Infant
MH  - Oxygen Saturation
MH  - Pregnancy
MH  - *Pregnancy Complications, Infectious/drug therapy
MH  - Pregnant Women
MH  - SARS-CoV-2
MH  - *COVID-19 Drug Treatment
PMC - PMC7797739
OTO - NOTNLM
OT  - COVID-19
OT  - pregnant
OT  - recovery
OT  - remdesivir
OT  - ventilation
EDAT- 2020/10/09 06:00
MHDA- 2021/12/15 06:00
PMCR- 2020/10/08
CRDT- 2020/10/08 17:14
PHST- 2020/07/31 00:00 [received]
PHST- 2020/10/09 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
PHST- 2020/10/08 17:14 [entrez]
PHST- 2020/10/08 00:00 [pmc-release]
AID - 5919737 [pii]
AID - ciaa1466 [pii]
AID - 10.1093/cid/ciaa1466 [doi]
PST - ppublish
SO  - Clin Infect Dis. 2021 Dec 6;73(11):e3996-e4004. doi: 10.1093/cid/ciaa1466.